Matthew L. Posard, Director at Nautilus Biotechnology, Inc. (NAUT), bought 50,000 shares at $4.57 ($226K) on 2021-11-30, disclosed to the SEC on 2021-12-01.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.57 | 20,000 | $91K | 40.5% |
| 2 | $4.45 | 10,000 | $45K | 19.7% |
| 3 | $4.46 | 10,000 | $45K | 19.8% |
| 4 | $4.50 | 10,000 | $45K | 20.0% |
| Total | $4.51 avg | 50,000 | $226K | 100% |
| Filing → |
| HALO | SELL | 2024-08-14 | $2.3M | — | Filing → |
| HALO | SELL | 2024-06-13 | $1.0M | — | Filing → |
| HALO | SELL | 2022-12-06 | $1.7M | — | Filing → |